Company / Free Cash Flow
NOVAVAX INC Free Cash Flow History
FY2016-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$97.0M
FY2022
5-year range
-$97.0M / $265.5M
FY2018-FY2022
Trend
-136.5%
vs FY2021
Sector context
#107 of 194
Health Care
What the data says
At -$97M, NOVAVAX INC's free cash flow ranks #107 of 194 in the Health Care sector.
Based on SEC 10-K filings.
-$97M in FY2022.
Remained stable around -$97M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#107 of 194 in Health CareTop 55% of 194This company -$97.0M Sector average $470.8M
▼
-120.6% below sector average
Key checks
Key Insights
- In FY2022, free cash flow decreased 136.5% year-over-year.
- Ranks #107 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2021.
- Lowest free cash flow in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score -0.87 (distress zone, below 1.8 threshold)
- Negative profit margin: -27.5%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | -$97.0M | -136.5% |
| FY2021 | $265.5M | +373.2% |
| FY2020 | -$97.2M | +34.6% |
| FY2019 | -$148.7M | +46.3% |
| FY2018 | -$277.0M | -91.9% |
| FY2017 | -$144.4M | -94.3% |
| FY2016 | -$74.3M | -45.2% |
As of FY2022 · SEC 10-K · Updated Jun 30, 2026